Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Ductal, Lobular, and Medullary

ClinicalTrials.gov lists 637 trials for Neoplasms, Ductal, Lobular, and Medullary or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 38.

MeSH D018299 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 82 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 160 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 53 Phase 4 Phase 4 10 Not applicable Not applicable 150 Observational Observational 137 Phase 1 Phase 1 82 Phase 1/2 Phase 1/2 37 Phase 2 Phase 2 160 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 53 Phase 4 Phase 4 10 Not applicable Not applicable 150 Observational Observational 137

Trials per phase (log scale)

1 more section with rows

Get the Neoplasms, Ductal, Lobular, and Medullary report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Ductal, Lobular, and Medullary trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 38

1991: 1 trials (Observational 1) 1994: 1 trials (Phase 2 1) 1995: 1 trials (Phase 2 1) 1996: 3 trials (Observational 2, Phase 1 1) 1997: 8 trials (Observational 2, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 1998: 3 trials (Phase 3 2, Phase 1/2 1) 1999: 2 trials (Phase 3 1, Phase 1 1) 2000: 4 trials (Phase 3 1, Phase 1 3) 2001: 6 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 2) 2002: 10 trials (Not applicable 1, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2003: 16 trials (Observational 2, Not applicable 6, Phase 3 3, Phase 2 4, Phase 1 1) 2004: 19 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 9, Phase 1/2 1, Phase 1 3) 2005: 20 trials (Observational 3, Not applicable 4, Phase 3 2, Phase 2 6, Phase 1 5) 2006: 20 trials (Observational 4, Not applicable 6, Phase 3 2, Phase 2 8) 2007: 23 trials (Observational 2, Not applicable 9, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 4) 2008: 29 trials (Observational 7, Not applicable 6, Phase 4 2, Phase 3 4, Phase 2 7, Phase 1 3) 2009: 24 trials (Observational 7, Not applicable 7, Phase 3 1, Phase 2 4, Phase 1/2 3, Phase 1 2) 2010: 23 trials (Observational 5, Not applicable 2, Phase 3 3, Phase 2 8, Phase 1 5) 2011: 22 trials (Observational 5, Not applicable 5, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2012: 21 trials (Observational 3, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1/2 3, Phase 1 2) 2013: 21 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 2) 2014: 21 trials (Observational 5, Not applicable 7, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 1) 2015: 25 trials (Observational 5, Not applicable 7, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1/2 3, Phase 1 3) 2016: 25 trials (Observational 4, Not applicable 8, Phase 3 5, Phase 2 3, Phase 1/2 1, Phase 1 4) 2017: 26 trials (Observational 2, Not applicable 8, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 1) 2018: 26 trials (Observational 11, Not applicable 5, Phase 3 1, Phase 2 3, Phase 1 6) 2019: 29 trials (Observational 6, Not applicable 9, Phase 4 1, Phase 3 1, Phase 2 7, Phase 1/2 3, Phase 1 2) 2020: 25 trials (Observational 5, Not applicable 9, Phase 3 2, Phase 2 7, Phase 1 2) 2021: 23 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2022: 24 trials (Observational 10, Not applicable 3, Phase 4 1, Phase 2 3, Phase 1/2 3, Phase 1 4) 2023: 23 trials (Observational 5, Not applicable 5, Phase 4 1, Phase 3 2, Phase 2 5, Phase 1/2 3, Phase 1 2) 2024: 34 trials (Observational 11, Not applicable 4, Phase 2 15, Phase 1/2 1, Phase 1 3) 2025: 38 trials (Observational 8, Not applicable 11, Phase 4 1, Phase 3 2, Phase 2 9, Phase 1/2 1, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 32
2025 38
2024 34
2023 23
2022 24
2021 23
2020 25
2019 29
2018 26
2017 26

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 41 trials starting in 2026 and about 40 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 69 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 380 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Ductal, Lobular, and Medullary trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 82
Phase 1/2 37
Phase 2 160
Phase 2/3 4
Phase 3 53
Phase 4 10
Not applicable 150
Observational 137
Expanded access 4

How many Neoplasms, Ductal, Lobular, and Medullary trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 30
Recruiting 97
Enrolling by invitation 5
Active, not recruiting 67
Completed 286

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Ductal, Lobular, and Medullary trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 38
Eli Lilly and Company 6

Which drugs are being tested for Neoplasms, Ductal, Lobular, and Medullary? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 12
NAB paclitaxel 12
Anastrozole 11
Cytoxan 9
TRASTUZUMAB 9

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tamoxifen Pill 32
Radiation Therapy 19
Letrozol (Femara, Novartis) 18
ZD6474, Vandetanib 14
Adjuvant Therapy 14

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Ductal, Lobular, and Medullary trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 411 16
Sepsis 238 19
Abdominal pain 223 21
Pyrexia 199 13
Vomiting 183 23

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Ductal, Lobular, and Medullary? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. British journal of cancer 2003 Yes
Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Annals of surgery 1997 Yes
Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. British journal of cancer 2003 No

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages